ReviewParasitology2018
The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design.
Review in Parasitology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion.Frontiers in cellular and infection microbiology · 2026Article
- Computational Structural Comparison of Toxoplasma gondii CDPK1 and Human BUB1 kinases: Implications for Selective Inhibitor Design.ACS omega · 2025Article
- Treatment with BKI-1748 afterAntimicrobial agents and chemotherapy · 2025Article
- Calcium-binding protein TgpCaBP regulates calcium storage of the zoonotic parasiteMicrobiology spectrum · 2024Article
- An Early Treatment With BKI-1748 Exhibits Full Protection Against Abortion and Congenital Infection in Sheep Experimentally Infected With Toxoplasma gondii.The Journal of infectious diseases · 2024Article
- The Dually Localized EF-Hand Domain-Containing Protein TgEFP1 Regulates the Lytic Cycle ofCells · 2022Article
- Common Molecular Targets of a Quinolone Based Bumped Kinase Inhibitor inInternational journal of molecular sciences · 2022Article
- Toxoplasmosis: Current and Emerging Parasite Druggable Targets.Microorganisms · 2021Review
- Promising Drug Targets and Compounds with Anti-Microorganisms · 2021Review
- Oxidative Stress as a Possible Target in the Treatment of Toxoplasmosis: Perspectives and Ambiguities.International journal of molecular sciences · 2021Review
- Questing functions and structures of hypothetical proteins from Campylobacter jejuni: a computer-aided approach.Bioscience reports · 2020Article
- Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy.Antimicrobial agents and chemotherapy · 2019Article
- Calcium signaling and the lytic cycle of the Apicomplexan parasite Toxoplasma gondii.Biochimica et biophysica acta. Molecular cell research · 2018Review
- Microbial protein targets: towards understanding and intervention.Parasitology · 2018Article
- Calcium-dependent Protein Kinases in Malaria Parasite Development and Infection.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The apicomplexan protozoan parasites include the causative agents of animal and human diseases ranging from malaria (Plasmodium spp.) to toxoplasmosis (Toxoplasma gondii). The complex life cycle of T. gondii is regulated by a unique family of calcium-dependent protein kinases (CDPKs) that have become the target of intensive efforts to develop new therapeutics. In this review, we will summarize structure-based strategies, recent successes and future directions in the pursuit of specific and selective inhibitors of T. gondii CDPK1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.